Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Elevance Health (ELV) to $483 from $495 and keeps an Overweight rating on the shares as the firm updates Managed Care estimates post-election. All estimates assume the expiration of enhanced exchange subsidies for 2026, Wells notes. The firm believes Medicare Advantage risk/reward improves with Republicans, although areas of concern still exist.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Omega exits stakes in Devon, Las Vegas Sands, KBR, and Paramount Global
- Elevance Health price target lowered to $505 from $585 at Mizuho
- Elevance Health price target lowered to $495 from $593 at Wells Fargo
- Elevance sues U.S. over Medicare star ratings, Bloomberg says
- Molina Healthcare price target raised to $345 from $335 at Stephens